Other cancer vaccine studies largely reverted to the model antigen chicken ovalbumin (OVA) expressing LLC-OVA tumour cells.54 It is conceivable that the lack of immune-dominant antigens in LLC1 tumours further drives the shift of the VSV-GP treatment-induced CD8+ T cell response towards a predominant antiviral rather than anti-tumour immunity. The gene discussed is CD8A; the disease is neoplasm.